Senior Director of Trade and Channel Management

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.   Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.  Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.  Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.  If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.   About the Role >>> Senior Director of Trade and Channel Management   As the Senior Director of US Trade and Channel Management reporting to the Vice President of Market Access, you will be responsible for the strategic design, implementation, and optimization of a high-performing distribution network that ensures patient access while maximizing commercial value. As a key leader within the U.S. Market Access function, you will oversee the total distribution ecosystem, including Specialty Pharmacy, Distribution and 3PL, while driving the long-term roadmap for trade operations and ensuring the organization is positioned to scale for future therapeutic innovations.    This role is based out of either our Boston or San Francisco office and will require approximately 20%   travel.  Your work will  primarily  encompass:  Strategic Trade & Distribution Architecture   Define and lead the long-term U.S. distribution strategy and the design of a distribution network to support the launch of our future oncology product(s), including a selection process to select key externals partners (ie. SP, SD, 3PL, etc) Provide active account management for specialty pharmacies, wholesalers/distributors, 3PL and other key trade partners to support product availability, service performance, and operational excellence Establish, monitor, and manage key performance indicators, service-level expectations, inventory metrics, dispense data, and reporting requirements for channel partners; hold partners accountable while maintaining strong relationships Ensure patient accessibility to product through trade partners and specialty pharmacies while supporting compliant processes and appropriate operational controls Lead cross-functional teams with Patient Services, Commercial Operations/Analytics, Finance, IT, Field Sales, Legal/Compliance, Contracting, and Supply Chain to implement channel strategies, improve workflows, strengthen data quality, and track progress against established goals Serve as the lead negotiator for enterprise-level contracts with major Wholesalers, Specialty Distributors, and Specialty Pharmacies to optimize channel fee structures and service requirements Develop and implement an optimized distribution and contracting strategy which can anticipate industry shifts and proactively adapt the distribution model to maintain a competitive advantage  Oversee launch readiness for activities within the Trade and Distribution as we prepare for the launch our lead clinical asset as well as all pipeline assets and lifecycle management initiatives  Lead transformation initiatives in Trade & Distribution including process redesign, systems modernization, vendor optimization, and automation to improve efficiency, scalability, and data accuracy    Forecasting, Financial Governance & GTN   Own the trade-related components of the Gross-to-Net (GTN) strategy, providing executive leadership with visibility into channel costs, inventory fluctuations, and potential financial risks  Drive the integration of channel data into enterprise forecasting models to ensure high-accuracy demand planning and inventory management  Implement advanced analytics to monitor channel health, utilizing data-driven insights to mitigate product diversion, stockpiling, or supply disruptions  Establish and evo